Share this Page:
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending use of cabozantinib (Cabometyx) as a treatment option for people with untreated advanced renal cell carcinoma (RCC).
Clinical trials have shown that patients treated with cabozantinib in the first-line had a reduced risk of disease progression or death by 52% compared to patients treated with first-line sunitinib. The approval is based on data from the phase 2 CABOSUN trial, which showed improvements in progression-free survival (PFS) for patients on cabozantinib compared to those who were given sunitinib (8.6 months with cabozantinib versus 5.3 months for sunitinib).
The final guidance can be found on the NICE website here, along with information for the public.